Nasus Pharma CEO buys 6,550 NSRX shares

Nasus Pharma Ltd Chief Executive Officer and director Dan Benjamin Teleman reported an open-market purchase of 6,550 Ordinary Shares at $3.10 per share.

Rhea-AI Filing Summary

Nasus Pharma Ltd Chief Executive Officer and director Dan Benjamin Teleman reported an open-market purchase of 6,550 Ordinary Shares at $3.10 per share. Following this transaction, he directly owns 163,541 Ordinary Shares in total. This holding includes 30,696 Ordinary Shares and 132,845 additional Ordinary Shares that are issuable from share options exercisable within 60 days, highlighting a meaningful option-based exposure alongside his common share position.

Insider Trade Summary

Net Buyer: 6,550 shares

Net Buy 1 txn

Insider Teleman Dan Benjamin

Role Chief Executive Officer

Bought 6,550 shs ($20K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	6,550	$3.10	$20K

Holdings After Transaction: Ordinary Shares — 163,541 shares (Direct)

Footnotes (1)

1. F1. Consists of: (i) 30,696 ordinary shares, no par value per share ("Ordinary Shares"), and (ii) 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days.

Key Figures

Shares purchased: 6,550 shares Purchase price: $3.10/share Total direct holdings after trade: 163,541 shares +2 more

5 metrics

Shares purchased 6,550 shares Open-market purchase of Ordinary Shares on June 17, 2026

Purchase price $3.10/share Price per Ordinary Share in reported transaction

Total direct holdings after trade 163,541 shares Ordinary Shares directly owned following the purchase

Current Ordinary Shares held 30,696 shares Ordinary Shares component of CEO’s holdings

Options exercisable within 60 days 132,845 shares Ordinary Shares issuable from outstanding share options

Key Terms

open-market purchase, Ordinary Shares, share options

3 terms

open-market purchase financial

"reported an open-market purchase of 6,550 Ordinary Shares at $3.10 per share"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Ordinary Shares financial

"open-market purchase of 6,550 Ordinary Shares at $3.10 per share"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

share options financial

"Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days"

Share options are contracts that give someone the right, but not the obligation, to buy a company’s stock at a predetermined price for a limited time—think of them like a coupon to purchase shares later at a set price. They matter to investors because when exercised they increase the number of outstanding shares (dilution), can change management incentives and company value, and represent a potential future claim on profits or equity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nasus Pharma (NSRX) CEO Dan Benjamin Teleman report in this Form 4?

He reported an open-market purchase of 6,550 Ordinary Shares at $3.10 per share. After the trade, he directly holds 163,541 Ordinary Shares, combining his existing stake with newly bought shares and options exercisable within 60 days.

How many Nasus Pharma (NSRX) shares does the CEO hold after the reported transaction?

After the transaction, he directly holds 163,541 Ordinary Shares. This figure consists of 30,696 Ordinary Shares already owned plus 132,845 Ordinary Shares that can be acquired through share options that are exercisable within 60 days of the reporting date.

What was the purchase price for the Nasus Pharma (NSRX) shares in the CEO’s Form 4?

The CEO’s Form 4 shows an open-market purchase of 6,550 Ordinary Shares at a price of $3.10 per share. This price applies specifically to the newly acquired shares reported for the transaction dated June 17, 2026.

What portion of the Nasus Pharma (NSRX) CEO’s position comes from share options?

According to the filing footnote, 132,845 of the 163,541 Ordinary Shares are issuable upon exercise of outstanding share options. These options are exercisable within 60 days, indicating a substantial option-based component to the CEO’s overall equity exposure.

Is the Nasus Pharma (NSRX) CEO’s transaction a buy or sell according to the Form 4?

The Form 4 classifies the transaction as a purchase, using transaction code “P” for an open-market transaction. The filing’s normalized data identifies the direction as a buy, with 6,550 Ordinary Shares acquired on June 17, 2026 and no reported sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 07:12 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Teleman Dan Benjamin

(Last) (First) (Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO 6100201

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/17/2026		P		6,550	A	$3.1	163,541(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of: (i) 30,696 ordinary shares, no par value per share ("Ordinary Shares"), and (ii) 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days.

	/s/ Dan Benjamin Teleman	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)